Welcome to our dedicated page for Anteris Technologies Global SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Anteris Technologies Global's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Anteris Technologies Global's regulatory disclosures and financial reporting.
Anteris Technologies Global Corp. has a resale registration covering up to 9,103,796 shares of common stock that may be sold by existing stockholders under a prior Form S-1. This prospectus supplement adds information from recent current reports, including a new capital raise. The company entered into an underwritten public offering of 34,782,609 shares, plus an additional 5,217,391 shares sold under the underwriters’ option, at $5.75 per share, and a concurrent private placement of 15,652,173 shares at the same price to a Medtronic subsidiary. Combined gross proceeds from the offering and private placement are expected to be approximately $320 million, before fees and expenses. Anteris plans to use the cash to fund its DurAVR THV pivotal trial, expand manufacturing, support v2vmedtech research and development, and for working capital and general corporate purposes.
Anteris Technologies Global Corp. reported that Medtronic plc, through a wholly owned subsidiary, is making a strategic equity investment in the company. The investment is structured under a stock purchase agreement dated January 20, 2026 between Anteris and the Medtronic subsidiary.
On January 22, 2026, Anteris and Medtronic issued a joint press release about this transaction, which is furnished as Exhibit 99.1. The disclosure is provided under Regulation FD, meaning it is intended to share the same information with all market participants at the same time.
Anteris Technologies Global Corp. entered into an underwritten public offering and a concurrent private placement of its common stock. The company agreed to sell 34,782,609 shares in the offering at $5.75 per share, and granted underwriters a 30-day option for 5,217,391 additional shares, which was exercised in full. It also agreed to sell 15,652,173 shares at $5.75 per share in a private placement to Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc.
The combined transactions are expected to generate approximately $320 million in gross proceeds before fees and expenses. Anteris plans to use the net proceeds, together with existing cash, to support its next stage of growth, including the global pivotal PARADIGM Trial for its DurAVR® Transcatheter Heart Valve, expansion of manufacturing capabilities, funding ongoing research and development for v2vmedtech, inc., and for working capital and other general corporate purposes.
Anteris Technologies Global Corp. is issuing 34,782,609 shares of common stock at $5.75 per share in a primary public offering on Nasdaq. The deal is expected to raise approximately $189.8 million in gross proceeds before expenses, with net proceeds estimated at about $187.4 million, or $215.6 million if underwriters fully exercise a 5,217,391‑share option. Concurrently, a Medtronic plc subsidiary has agreed to buy 15,652,173 additional shares in a private placement at the same price, with expected net proceeds of about $84.4 million that are not registered in this prospectus.
After the offering and private placement, Anteris expects to have 86,497,152 shares outstanding, including CDIs. Proceeds, together with existing cash, will fund the PARADIGM pivotal trial of the DurAVR THV system for severe aortic stenosis, expand manufacturing capacity, and support R&D, including for v2vmedtech, plus working capital. The company is a development‑stage structural heart business with preliminary cash of about $12.6 million as of December 31, 2025 and an auditor going‑concern explanatory paragraph, and it acknowledges that investors in this offering will experience immediate dilution of $2.50 per share.
BlackRock, Inc. has updated its ownership disclosure for Anteris Technologies Global Corp common stock. BlackRock reports beneficial ownership of 2,026,967 shares, representing 4.9% of the outstanding common stock. It reports sole voting power over 1,997,796 shares and sole dispositive power over the full 2,026,967 shares, with no shared voting or dispositive power.
The filing explains that these holdings are attributed to certain BlackRock business units, and do not include any securities held by other disaggregated units. Various underlying persons have the right to receive dividends or sale proceeds from these shares, but no single person has more than five percent of the total outstanding common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Anteris Technologies Global Corp. is registering $200,000,000 of common stock in a primary offering. The company has also granted underwriters a 30-day option to buy up to an additional $30,000,000 of common stock. Concurrently, a Covidien subsidiary of Medtronic may purchase up to $90.0 million of common stock in a private placement at the same price as this offering, for a stake between 16.0% and 19.99% of shares outstanding after the deals close.
Anteris develops the DurAVR THV System for treating severe aortic stenosis and is running the global PARADIGM pivotal trial following FDA IDE and initial European approvals. The company remains a development-stage business with recurring losses and preliminary cash and cash equivalents of about $12.6 million as of December 31, 2025, and its auditors have raised substantial doubt about its ability to continue as a going concern. Proceeds from this offering and the private placement are intended to fund PARADIGM trial execution, manufacturing expansion, R&D for v2vmedtech and general corporate purposes, and Anteris is also exploring up to $100 million of additional debt financing.
Anteris Technologies Global Corp. reported an equity transaction by its Chief Operating Officer and director. On December 16, 2025, the reporting person acquired 166,666 shares of common stock through the vesting and settlement of restricted stock units, recorded as a code "M" transaction. On the same date, 65,584 shares were disposed of in a code "F" transaction at a price of $4.95 per share, typically reflecting shares withheld to cover taxes. After these transactions, the reporting person directly held 101,082 shares of common stock.
The derivative table shows this activity came from a grant of 500,000 restricted stock units awarded on December 16, 2024, which vest in approximately equal installments on December 16 of 2025, 2026, and 2027, subject to continued service. Following the reported transaction, 333,334 restricted stock units remained beneficially owned.
Anteris Technologies Global Corp. Chief Financial Officer Matthew McDonnell reported the vesting of a portion of his equity award and the related share issuance. On December 16, 2024, he was granted 83,333 restricted stock units (RSUs), scheduled to vest in approximately equal installments on December 16, 2025, 2026 and 2027, subject to his continued service. On December 16, 2025, 27,777 RSUs vested and converted on a one-for-one basis into common stock, recorded as an acquisition of 27,777 shares at a price of $0.
Following this transaction, McDonnell beneficially owns 27,777 common shares indirectly through Citicorp Nominees Pty Ltd and 55,556 RSUs directly, each RSU convertible into one share of common stock. The common stock received is represented as CHESS Depositary Interests traded on the Australian Securities Exchange.
Anteris Technologies Global Corp. chief executive officer and director Wayne Paterson reported equity award activity involving the company’s common stock. On December 16, 2025, a tranche of 333,333 restricted stock units (RSUs) converted on a one-for-one basis into the same number of common shares, reflecting previously granted equity compensation.
The filing also shows a disposition of 163,213 common shares at $4.95 per share, typically consistent with share sales to cover tax withholding on vested awards. After these transactions, Paterson held 182,727 common shares indirectly through Citibank, N.A. London as custodian and 20,334 shares directly, along with 666,667 RSUs that remain outstanding. These RSUs are part of a 1,000,000-unit grant awarded on December 16, 2024, vesting in roughly equal installments on December 16 of 2025, 2026, and 2027, which stockholders approved on December 3, 2025.
Anteris Technologies Global Corp. director John Seaberg reported the vesting and conversion of restricted stock units into common stock. On 12/16/2025, 27,777 restricted stock units were converted into 27,777 shares of common stock in a transaction coded "M," increasing his directly held common shares to 43,635. He also holds 3,852 shares indirectly through Citibank, N.A. London as custodian.
The derivative table shows these 27,777 restricted stock units converting at an exercise price of $0 into common stock, leaving 55,556 restricted stock units beneficially owned following the transaction. These units come from a contingent grant of 83,333 restricted stock units awarded on December 16, 2024, which vest in approximately equal installments on December 16, 2025, 2026 and 2027, subject to continued service and approval previously obtained from stockholders on December 3, 2025.